Prediction of human metabolism of the sedative-hypnotic zaleplon using chimeric mice transplanted with human hepatocytes

Xenobiotica

Volumn 43, Issue 11, 2013, Pages 956-962

  Tanoue, Chiaki ^a   Sugihara, Kazumi ^b   Uramaru, Naoto ^c   Tayama, Yoshitaka ^b   Watanabe, Yoko ^a,c   Horie, Toru ^d   Ohta, Shigeru ^a   Kitamura, Shigeyuki ^c  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA INTERNATIONAL UNIVERSITY   (Japan)

^c NIHON PHARMACEUTICAL UNIVERSITY   (Japan)

^d DeThree Research Laboratories   (Japan)

Author keywords

Aldehyde oxidase; Cytochrome P450; Human liver; Human chimeric mice; Mouse liver; Rat chimeric mice; Zaleplon

Indexed keywords

ALDEHYDE OXIDASE; CYTOCHROME P450; DESETHYL ZALEPLON; OXIDOREDUCTASE; UNCLASSIFIED DRUG; ZALEPLON;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER CYTOSOL; LIVER MICROSOME; MALE; MOUSE; NONHUMAN; PREDICTION; RAT;

ACETAMIDES; ADMINISTRATION, ORAL; ADOLESCENT; ANIMALS; CYTOSOL; HEPATOCYTES; HUMANS; HYPNOTICS AND SEDATIVES; LIVER; MALE; METABOLIC NETWORKS AND PATHWAYS; MICE; MICE, TRANSGENIC; MICROSOMES, LIVER; OXIDOREDUCTASES; PYRIMIDINES; RATS; TIME FACTORS;

EID: 84885159847     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2013.788232     Document Type: Article

References (41)

1. Aoki K, Kashiwagura Y, Horie T, et al. (2006). Characterization of humanized liver from chimeric mice using coumarin as a human CYP2A6 and mouse CYP2A5 probe. Drug Metab Pharmacokinet 21: 277-85
2. Beedham C. (1985). Molybdenum hydroxylases as drug-metabolizing enzymes. Drug Metab Rev 16:119-56
3. Beer B, Ieni JR, Wu WH, et al. (1994). A placebo-controlled evaluation of single, escalating doses of CL-284,846, a non-benzodiazepine hypnotic. J Clin Pharmacol 34:335-44
4. Chaudhary I, DeMaio W, Kantrowitz J. (1994). Species comparison of in vitro and in vivo metabolism of CL284,846, a non-benzodiazepine sedative/hypnotic agent. Pharm Rev (NY) 11:319
5. Garattini E, Mendel R, Romao MJ, et al. (2003). Mammalian molybdoflavoenzymes, an expanding family of proteins: Structure, genetics, regulation, function and pathophysiology. Biochem J 372:15-32
6. Inoue T, Nitta K, Sugihara K, et al. (2008). CYP2C9-catalyzed metabolism of S-warfarin to 7-hydroxywarfarin in vivo and in vitro in chimeric mice with humanized liver. Drug Metab Dispos 36: 2429-33
7. Inoue T, Sugihara K, Ohshita H, et al. (2009). Prediction of human disposition toward S-3H-warfarin using chimeric mice with humanized liver. Drug Metab Pharmacokinet 24:153-60
8. Kamimura H, Nakada N, Suzuki K, et al. (2010). Assessment of chimeric mice with humanized liver as a tool for predicting circulating human metabolites. Drug Metab Pharmacokinet 25:223-35
9. Katoh M, Matsui T, Nakajima M, et al. (2004). Expression of human cytochromes P450 in chimeric mice with humanized liver. Drug Metab Dispos 32:1402-10
10. Katoh M, Matsui T, Nakajima M, et al. (2005b). In vivo induction of human cytochrome P450 enzymes expressed in chimeric mice with humanized liver. Drug Metab Dispos 33:754-63
11. Katoh M, Matsui T, Okumura H, et al. (2005a). Expression of human phase II enzymes in chimeric mice with humanized liver. Drug Metab Dispos 33:1333-40
12. Katoh M, Sawada T, Soeno Y, et al. (2007). In vivo drug metabolism model for human cytochromes P450 enzyme using chimeric mice with humanized liver. J Pharm Sci 96:428-37
13. Katoh M, Tateno C, Yoshizato K, et al. (2008). Chimeric mice with humanized liver. Toxicology 246:9-17
14. Katoh M, Yokoi T. (2007). Application of chimeric mice with humanized liver for predictive ADME. Drug Metab Rev 39:145-57
15. Kawashima K, Hosoi K, Naruke T, et al. (1999). Aldehyde oxidasedependent marked species difference in hepatic metabolism of the sedative-hypnotic, zaleplon, between monkeys and rats. Drug Metab Dispos 27:422-8
16. Kitamura S, Nitta K, Tayama Y, et al. (2008). Aldehyde oxidasecatalyzed metabolism of N1-methylnicotinamide in vivo and in vitro in chimeric mice with humanized liver. Drug Metab Dispos 36:1202-5
17. Kitamura S, Sugihara K, Nakatami K, et al. (1999). Variation of hepatic methotrexate 7-hydroxylase activity in animals and humans. IUBMB Life 48:607-11
18. Kitamura S, Sugihara K, Ohta S. (2006). Drug-metabolizing ability of molybdenum hydroxylase. Drug Metab Pharmacokinet 21:83-98
19. Lake BG, Ball SE, Kao J, et al. (2002). Metabolism of zaleplon by human liver: Evidence for involvement of aldehyde oxidase. Xenobiotica 32:835-47
20. Lootens L, Meuleman P, Leroux-Roels G, et al. (2011). Metabolic studies with promagnon, methylclostebol and methasterone in the uPAθ/θ-SCID chimeric mice. J Steroid Biochem Mol Biol 127: 374-81
21. Lootens L, Meuleman P, Pozo OJ, et al. (2009). uPAθ/θ-SCID mouse with humanized liver as a model for in vivo metabolism of exogenous steroids: Methandienone as a case study. Clin Chem 55:1783-93
22. Nishimura M, Yokoi T, Tateno C, et al. (2005). Induction of human CYP1A2 and CYP3A4 in primary culture of hepatocytes from chimeric mice with humanized liver. Drug Metab Pharmacokinet 20: 121-6
23. Obach RS. (2004). Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab Dispos 32:89-97
24. Obach RS, Huynh P, Allen MC, et al. (2004). Human liver aldehyde oxidase: Inhibition by 239 drugs. J Clin Pharmacol 44:7-19
25. Pryde DC, Dalvie D, Hu Q, et al. (2010). Aldehyde oxidase: An enzyme of emerging importance in drug discovery. J Med Chem 53:8441-60
26. Radl S, Blahovcova M, Placek L, et al. (2010). Synthesis of some impurities and/or degradation products of zaleplon. J Heterocyclic Chem 47:276-83
27. Renwick AB, Ball SE, Tredger JM, et al. (2002). Inhibition of zaleplon metabolism by cimetidine in the human liver: In vitro studies with subcellular fractions and precision-cut liver slices. Xenobiotica 32: 849-62
28. Renwick AB, Mistry H, Ball SE, et al. (1998). Metabolism of zaleplon by human hepatic microsomal cytochrome P450 isoforms. Xenobiotica 28:337-48
29. Rosen AS, Fournie P, Darwish M, et al. (1999). Zaleplon pharmacokinetics and absolute bioavailability. Biopharm Drug Dispos 20:171-75
30. Samuelsson K, Pickup K, Sarda S, et al. (2012). Pharmacokinetics and metabolism of midazolam in chimeric mice with humanized livers. Xenobiotica 42:1128-37
31. Sanoh S, Horiguchi A, Sugihara K, et al. (2012b). Prediction of in vivo hepatic clearance and half-life of drug candidates using chimeric mice with humanized liver. Drug Metab Dispos 40:322-8
32. Sanoh S, Horiguchi A, Sugihara K, et al. (2012c). Predictability of metabolism of ibuprofen and naproxen using chimeric mice with human hepatocytes. Drug Metab Dispos 40:2267-72
33. Sanoh S, Nozaki K, Murai H, et al. (2012a). Prediction of human metabolism of FK3453 by aldehyde oxidase using chimeric mice transplanted with human or rat hepatocytes. Drug Metab Dispos 40: 76-82
34. Schulz-Utermoehl T, Sarda S, Foster JR, et al. (2012). Evaluation of the pharmacokinetics, biotransformation and hepatic transporter effects of troglitazone in mice with humanized livers. Xenobiotica 42:503-17
35. Strom SC, Davila J, Grompe M. (2010). Chimeric mice with humanized liver: Tools for the study of drug metabolism, excretion, and toxicity. Methods Mol Biol 640:491-509
36. Sugihara K, Katsuma Y, Kitamura S, et al. (2000). Cynomolgus monkey liver aldehyde oxidase: Extremely high oxidative activity and an attempt at purification. Comp Biochem Physiol (C) 126:53-60
37. Sugihara K, Kitamura S, Tatsumi K, et al. (1997). Differences in aldehyde oxidase activity in cytosolic preparations of human and monkey liver. Biochem Mol Biol Int 41:1153-60
38. Tateno C, Yoshizane Y, Saito N, et al. (2004). Near completely humanized liver in mice shows human-Type metabolic responses to drugs. Am J Pathol 165:901-12
39. Vanover KE, Barret JE. (1994). Evaluation of the discriminative stimulus effects of the novel sedative-hypnotic CL284,846. Psychopharmacology 115:289-96
40. Vanover KE, Mangano RM, Barret JE. (1994). CL284,846, a novel sedative-hypnotic: Evaluation of its metabolites for pharmacological activity in vitro and in vivo. Drug Dev Res 33:39-45
41. Wu WH. (1996). Mass balance and pharmacokinetics of zaleplon, a nonbenzodiazepine sedative/hypnotic, in man. Pharmaceutical Res 13: S487